EMKinetics
Transdermal neuromodulation therapy for urinary incontinence.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
$8.0m | Series C | ||
| Total Funding | 000k | ||
EMKinetics, Inc. is a clinical-stage medical technology company that develops neuromodulation therapies for overactive bladder and urinary incontinence. The company's core technology, TranStim™, is a transdermal stimulation system designed to reduce urinary bladder overactivity by stimulating the posterior tibial nerve through the skin. This approach is based on the clinical evidence that posterior tibial nerve stimulation (PTNS) can lead to significant improvements for patients.
Founded in 2006 by Daniel Burnett, MD, and Marshall Stoller, MD, EMKinetics was the fourth spin-out from the medical device incubator TheraNova, LLC. Dr. Burnett, who also served as a director, received his M.D. and M.B.A. from Duke University and is an inventor on numerous patents. He has been instrumental in raising capital for multiple TheraNova spinouts. The company was headquartered in Campbell, California. Through multiple funding rounds, including a Series B and C, EMKinetics raised a total of $12.5 million from investors such as Oakwood Medical, Easton Capital Investment Group, and Allergan, Inc. In 2011, the company initiated a pivotal trial for its TranStim™ system involving 120 patients across several U.S. centers, with plans to seek CE mark and 510(k) clearance. However, some of its clinical trials were later terminated, and by February 2021, the company appeared to be inactive.
Keywords: transdermal nerve stimulation, urinary incontinence, neuromodulation therapy, overactive bladder, medical device, clinical-stage, TranStim, posterior tibial nerve stimulation, PTNS, Daniel Burnett, TheraNova, medtech, urology, urge incontinence, percutaneous stimulation